Literature DB >> 10160082

An assessment of the hidden and total antibiotic costs of four parenteral cephalosporins.

E T Smyth1, J G Barr, C A O'Neill, G M Hogg.   

Abstract

The aim of this study was to compare the hidden costs, and their impact on total antibiotic costs, of ceftriaxone therapy with those of cefotaxime, ceftazidime and cefuroxime in nosocomial infection. The total antibiotic costs of 7-day standard courses of the 4 cephalosporins were compared. The costs were divided into 3 parts: (i) the cost of the drug itself; (ii) the preparation and administration (labour) costs; and (iii) the consumables and waste costs. The latter 2 costs together comprised the hidden cost of an antibiotic course. Hidden costs were higher for cefotaxime, ceftazidime and cefuroxime, which are normally administered 3 times a day, than for ceftriaxone, which is administered once daily. The percentage contribution of hidden costs to total antibiotic costs increased with decreasing antibiotic cost, and were lower with higher dosages of all antibiotics. With cefotaxime, ceftazidime and cefuroxime, and with ceftriaxone at the lower dosage given by bolus intravenous (IV) injection, the labour component of hidden costs exceeded the consumables/waste component. However, when costs were calculated for ceftriaxone administered at the higher dosage by IV infusion, the costs of consumables and waste were greater than the labour costs. Ceftriaxone had the lowest hidden costs of all the antibiotics studied. The total antibiotic cost of low dosage ceftriaxone (1 g per dose) was comparable with that of cefuroxime, and was substantially less than the costs of cefotaxime and ceftazidime. At the high ceftriaxone dosage (2g per dose), the total antibiotic cost of cefuroxime was less than that of ceftriaxone; however, the total antibiotic cost of ceftriaxone remained substantially less than that of cefotaxime or ceftazidime.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 10160082     DOI: 10.2165/00019053-199508060-00008

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  10 in total

1.  Technique for calculation of the true costs of antibiotic therapy.

Authors:  J R Kerr; J G Barr; E T Smyth; J O'Hare
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-09       Impact factor: 3.267

2.  The value of oral antibiotic prophylaxis in biliary tract surgery.

Authors:  C S McArdle; C G Morran; L Pettit; C G Gemmell; J D Sleigh; G S Tillotson
Journal:  J Hosp Infect       Date:  1991-09       Impact factor: 3.926

Review 3.  Clinical application of the newer beta-lactam antibiotics.

Authors:  M Turck
Journal:  J Antimicrob Chemother       Date:  1988-07       Impact factor: 5.790

4.  Computerised calculation of the true costs of antibiotic therapy.

Authors:  J R Kerr; J G Barr; E T Smyth
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-08       Impact factor: 3.267

5.  Ceftriaxone versus cefotaxime in the treatment of septicemia in adults.

Authors:  A Ferencz; G Prinz; A Szalka; E Ban
Journal:  Chemotherapy       Date:  1989       Impact factor: 2.544

6.  Therapy of lower respiratory tract infections: a comparison of ceftriaxone and cefotaxime.

Authors:  P Barradas; M Zamith; W Videira; T Cardosa; R A Marques; R Avila
Journal:  Chemotherapy       Date:  1989       Impact factor: 2.544

7.  Once-daily therapy with ceftriaxone compared with daily multiple-dose therapy with cefotaxime for serious bacterial infections: a randomized, double-blind study.

Authors:  L A Mandell; M G Bergeron; A R Ronald; C Vega; G Harding; R Saginur; R Feld; R Duperval; S J Landis; L J Miedzinski
Journal:  J Infect Dis       Date:  1989-09       Impact factor: 5.226

8.  The in vitro antibacterial activity of ceftriaxone in comparison with nine other antibiotics.

Authors:  A M Emmerson; P A Lamport; D S Reeves; M J Bywater; H A Holt; R Wise; J Andrews; M J Hall
Journal:  Curr Med Res Opin       Date:  1985       Impact factor: 2.580

9.  Pharmacokinetics of ceftriaxone in humans.

Authors:  I H Patel; S Chen; M Parsonnet; M R Hackman; M A Brooks; J Konikoff; S A Kaplan
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

10.  Comparison of once daily ceftriaxone with gentamicin plus cefuroxime for treatment of serious bacterial infections.

Authors:  I M Hoepelman; M Rozenberg-Arska; J Verhoef
Journal:  Lancet       Date:  1988-06-11       Impact factor: 79.321

  10 in total
  4 in total

1.  Hidden costs of antibiotics.

Authors:  E T Smyth; J G Barr; G M Hogg
Journal:  Pharmacoeconomics       Date:  1996-07       Impact factor: 4.981

2.  Using cost of infection as a tool to demonstrate a difference in prophylactic antibiotic efficacy: a prospective randomized comparison of the pharmacoeconomic effectiveness of ceftriaxone and cefotaxime prophylaxis in abdominal surgery.

Authors:  John C Woodfield; Andre M Van Rij; Ross A Pettigrew; Antje van der Linden; Donna Bolt
Journal:  World J Surg       Date:  2005-01       Impact factor: 3.352

Review 3.  Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections.

Authors:  R N Brogden; C M Spencer
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

4.  Single daily dosing ceftriaxone and metronidazole vs standard triple antibiotic regimen for perforated appendicitis in children: a prospective randomized trial.

Authors:  Shawn D St Peter; Kuojen Tsao; Troy L Spilde; George W Holcomb; Susan W Sharp; J Patrick Murphy; Charles L Snyder; Ronald J Sharp; Walter S Andrews; Daniel J Ostlie
Journal:  J Pediatr Surg       Date:  2008-06       Impact factor: 2.545

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.